In a patient with a de Winter ECG pattern (proximal left anterior descending artery occlusion) undergoing streptokinase thrombolysis, should intravenous unfractionated heparin be given in addition to aspirin and clopidogrel (Plavix)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, IV unfractionated heparin should be given in addition to aspirin and clopidogrel when administering streptokinase for a de Winter ECG pattern (STEMI equivalent).

For patients receiving streptokinase thrombolysis with aspirin and clopidogrel, IV unfractionated heparin (UFH) is recommended and should be continued through any subsequent PCI. 1, 2, 1

Rationale for IV Heparin with Streptokinase

The 2013 ACC/AHA STEMI guidelines provide clear Class I recommendations for anticoagulation during fibrinolytic therapy:

  • Continue UFH through PCI, administering additional IV boluses as needed to maintain therapeutic activated clotting time (ACT) of 250-300 seconds (HemoTec) or 300-350 seconds (Hemochron) when no GP IIb/IIIa inhibitor is planned 1, 2, 1

  • For patients with high-risk features (anterior MI, pump failure, atrial fibrillation, left ventricular thrombus), IV UFH is specifically recommended during streptokinase administration 3

De Winter Pattern Context

The de Winter ECG pattern represents a STEMI equivalent indicating acute proximal LAD occlusion 4, 5, 6, 7. This is a high-risk presentation that:

  • Requires the same aggressive antithrombotic approach as conventional STEMI
  • Frequently involves unstable thrombotic lesions 5
  • May have suboptimal thrombolytic efficacy, making adjunctive anticoagulation even more critical 4

Specific Anticoagulation Protocol

Initial dosing for streptokinase with UFH:

  • UFH bolus: 60 units/kg (maximum 4000 units)
  • Maintenance infusion: 12 units/kg/hour (maximum 1000 units/hour)
  • Target aPTT: 50-70 seconds (1.5-2.0 times control)
  • Duration: At least 48 hours or until PCI/discharge 8

Important Caveats

Streptokinase-specific considerations:

  • Streptokinase activates both platelets and thrombin, creating prothrombotic effects that may exceed those of tissue plasminogen activator 9
  • While streptokinase produces fibrin degradation products with anticoagulant effects, these do not fully protect against reocclusion 9
  • The combination of aspirin, clopidogrel, and IV heparin with streptokinase increases bleeding risk but provides necessary protection against reocclusion 3

Alternative anticoagulants:

  • Enoxaparin may be preferred over UFH (Class IIb recommendation) and can be continued through PCI with dosing adjustments based on timing 1, 10
  • Fondaparinux is contraindicated as sole anticoagulant for PCI (Class III: Harm) due to catheter thrombosis risk 1

Clinical Algorithm

  1. Immediate administration (with streptokinase):

    • Aspirin 160-325 mg
    • Clopidogrel 300 mg loading dose
    • IV UFH bolus and infusion as above
  2. If proceeding to PCI (rescue or delayed):

    • Continue UFH through procedure
    • Administer additional boluses to maintain therapeutic ACT
    • Consider GP IIb/IIIa inhibitor for bailout if massive thrombus or no-reflow 10
  3. Post-procedure:

    • Discontinue anticoagulant after uncomplicated PCI 8
    • Continue aspirin indefinitely
    • Continue clopidogrel 75 mg daily for at least 30 days (bare metal stent) or 1 year (drug-eluting stent) 1, 2, 1

The evidence consistently supports triple antithrombotic therapy (aspirin + clopidogrel + IV heparin) for streptokinase administration in STEMI and STEMI-equivalents like the de Winter pattern, with careful monitoring for bleeding complications.

References

Research

Issues Regarding the Use of Heparin Following Streptokinase Therapy.

Journal of thrombosis and thrombolysis, 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.